VOR

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Vor Biopharma Inc

NASDAQ | VOR

32.29

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$214.05M

Market Cap

-

P/E Ratio

-273.6

EPS

$65.80

52 Week High

$2.62

52 Week Low

HEALTHCARE

Sector

VOR Chart

Recent Chart
Price Action

VOR Technicals

Tags:

VOR Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$3.5M
Total Revenue $0
Cost Of Revenue $3.5M
Costof Goods And Services Sold $3.5M
Operating Income -$121M
Selling General And Administrative $28M
Research And Development $93M
Operating Expenses $118M
Investment Income Net -
Net Interest Income $4.3M
Interest Income $4.3M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.5M
Income Before Tax -$117M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$117M
Comprehensive Income Net Of Tax -
Ebit -$117M
Ebitda -$113M
Net Income -$117M

Revenue & Profitability

Earnings Performance

VOR Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $143M
Total Current Assets $97M
Cash And Cash Equivalents At Carrying Value $82M
Cash And Short Term Investments $82M
Inventory -
Current Net Receivables -
Total Non Current Assets $46M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $10M
Other Current Assets $4.6M
Other Non Current Assets -
Total Liabilities $46M
Total Current Liabilities $19M
Current Accounts Payable $1.5M
Deferred Revenue -
Current Debt -
Short Term Debt $4.2M
Total Non Current Liabilities $28M
Capital Lease Obligations $32M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $32M
Other Current Liabilities $13M
Other Non Current Liabilities -
Total Shareholder Equity $97M
Treasury Stock -
Retained Earnings -$457M
Common Stock $13K
Common Stock Shares Outstanding $3.4M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$100M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $3.5M
Capital Expenditures $229K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $97M
Cashflow From Financing $53M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$117M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$3.5M
Total Revenue $0
Cost Of Revenue $3.5M
Costof Goods And Services Sold $3.5M
Operating Income -$121M
Selling General And Administrative $28M
Research And Development $93M
Operating Expenses $118M
Investment Income Net -
Net Interest Income $4.3M
Interest Income $4.3M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.5M
Income Before Tax -$117M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$117M
Comprehensive Income Net Of Tax -
Ebit -$117M
Ebitda -$113M
Net Income -$117M

VOR News

VOR Profile

Vor Biopharma Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Vor Biopharma Inc. is an innovative biopharmaceutical company based in Cambridge, Massachusetts, focused on pioneering hematopoietic stem cell (eHSC) therapies for the treatment of cancer. Leveraging proprietary technology platforms, Vor aims to create targeted and effective therapies that enhance the durable response and overall survival of patients. The company's commitment to advancing cell therapies positions it at the forefront of the rapidly evolving oncology landscape, making it a compelling prospect for institutional investors seeking exposure to next-generation cancer treatments.

VHAI
-25.00%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
NVTS
+21.14%
$9.97
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
APLD
+0.73%
$34.24
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
AMD
+0.40%
$215.76
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
RR
+8.95%
$6.45
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
IONQ
+16.19%
$82.09
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
MARA
+8.52%
$20.23
NOK
-1.31%
$5.25
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30
VHAI
-25.00%
$0.00
YYAI
-10.47%
$0.17
BURU
+7.74%
$0.51
CGBS
-39.47%
$0.03
ELBM
+325.45%
$7.02
PLUG
+14.03%
$3.90
RGTI
+25.02%
$54.91
GWH
+117.54%
$9.05
BITF
+28.33%
$5.39
NVDA
+2.81%
$188.32
ASST
-30.54%
$1.08
IONZ
-32.55%
$2.29
BYND
-48.50%
$1.03
NVTS
+21.14%
$9.97
INTC
+2.33%
$37.22
JOBY
+3.00%
$16.77
DNN
+6.94%
$3.08
GPUS
-10.39%
$0.43
CAN
+39.44%
$1.52
QBTS
+23.01%
$40.61
TSLA
+5.41%
$435.90
BBD
+0.98%
$3.09
F
+1.13%
$11.54
CLF
+4.93%
$13.83
AXDX
-61.36%
$0.03
NIO
+7.00%
$7.18
QS
+15.57%
$16.98
SOFI
+3.62%
$27.14
CRML
+55.40%
$23.28
ETHD
-12.82%
$3.33
CIFR
+19.85%
$20.34
ACHR
+6.68%
$12.77
RXRX
+3.94%
$5.53
SOUN
+10.25%
$19.14
DFLI
+44.03%
$1.57
APLD
+0.73%
$34.24
TLRY
-1.74%
$1.69
BTBT
+6.38%
$4.00
NAK
+31.03%
$2.66
AMD
+0.40%
$215.76
LAES
+13.30%
$6.13
ONDS
+17.24%
$10.81
DVLT
-10.52%
$1.70
MP
+21.34%
$95.06
USAR
+18.61%
$38.68
RR
+8.95%
$6.45
IREN
+7.31%
$64.14
AVGO
+9.87%
$356.70
UAMY
+36.85%
$16.71
ABAT
+36.59%
$9.22
PFE
-0.20%
$24.73
SNAP
+3.47%
$8.05
NAKA
-1.56%
$0.85
RIG
+3.89%
$3.20
IONQ
+16.19%
$82.09
AAL
+1.90%
$11.74
QUBT
+12.85%
$21.46
UUUU
+16.86%
$23.77
MARA
+8.52%
$20.23
NOK
-1.31%
$5.25
EOSE
+23.37%
$17.05
BMNR
+8.34%
$56.85
PLTR
+1.00%
$177.21
RMBL
+60.50%
$3.21
ADAP
-2.59%
$0.18
EPWK
-8.00%
$0.08
BULL
+2.98%
$11.74
ADD
-25.47%
$0.05
AAPL
+0.97%
$247.66
AMZN
+1.71%
$220.07
WULF
+3.62%
$14.00
XCH
+103.41%
$1.68
T
-1.08%
$25.59
HPE
+1.63%
$24.80
RF
+1.65%
$24.56
NB
+8.95%
$11.32
SRM
+53.27%
$10.30
BTG
+4.52%
$5.31
CLSK
+3.94%
$20.04
GDXD
-13.62%
$0.73
BAC
+0.43%
$48.86
QSI
+24.55%
$2.08
KDP
+2.32%
$26.42
RGTZ
-50.00%
$9.30
VALE
+2.41%
$11.01
SMR
+14.72%
$45.02
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
SLB
+1.73%
$32.27
ORCL
-1.34%
$292.95
ABEV
+1.42%
$2.14
BE
+26.52%
$109.91
WLGS
-5.57%
$0.04
TMC
+20.31%
$10.69
HOOD
+1.23%
$140.68
TMQ
+10.62%
$6.56
GRAB
+1.19%
$5.93
KDLY
-7.21%
$0.87
GGB
+2.85%
$3.24
ETWO
0.00%
$3.30
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.